The Semaglutide Study
Improving Patient Safety for Surgical Patients on Semaglutide: A Gastric Ultrasound Initiative
1 other identifier
observational
100
1 country
1
Brief Summary
The primary goal of this study is to evaluate the incidence of "full stomach" in fasting elective surgical patients on Semaglutide medication. The other goals are to study the impact of the time interval since the last dose of the medication on the incidence of full stomach and to develop evidence-based recommendations for the perioperative management of these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 25, 2024
CompletedFirst Submitted
Initial submission to the registry
April 10, 2024
CompletedFirst Posted
Study publicly available on registry
May 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2026
CompletedNovember 20, 2025
October 1, 2025
1.7 years
April 10, 2024
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of full stomach.
Frequency of full stomach in patients taking semaglutide and fasting before surgery. Analysis of the primary outcome will be based on a chi-square analysis.
Pre-Surgical fasting duration per guideline
Secondary Outcomes (2)
Any changes in anesthetic management from the a priori plan following the result of the gastric ultrasound examination.
Pre-operative anesthesia management plan
Impact of age, sex and the time since the last dose of Semaglutide, on the incidence of "full stomach".
Pre-Surgical fasting duration per guideline
Interventions
Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.
Eligibility Criteria
A cohort of 100 patients undergoing elective surgery while under treatment with Semaglutide for either diabetes or for losing weight.
You may qualify if:
- Patients scheduled for elective surgery at Toronto Western Hospital
- Aged ≥ 18 years of age
- American Society of Anaesthesia physical status classification I to III
- Patients being treated with Semaglutide for at least 1 month
You may not qualify if:
- Current pregnancy evidenced by positive urinary pregnancy test
- Previous surgery of the upper gastrointestinal tract
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anahi Perlas
Investigator-Sponsor
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 10, 2024
First Posted
May 20, 2024
Study Start
March 25, 2024
Primary Completion
November 30, 2025
Study Completion
March 31, 2026
Last Updated
November 20, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share